Visualizing hypothesis tests in survival analysis under anticipated delayed effects
Rattachement africain : ch, gb. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract What can be considered an appropriate statistical method for the primary analysis of a randomized clinical trial (RCT) with a time‐to‐event endpoint when we anticipate non‐proportional hazards owing to a delayed effect? This question has been the subject of much recent debate. The standard approach is a log‐rank test and/or a Cox proportional hazards model. Alternative methods have been explored in the statistical literature, such as weighted log‐rank tests and tests based on the Restricted Mean Survival Time (RMST). While weighted log‐rank tests can achieve high power compared to the standard log‐rank test, some choices of weights may lead to type‐I error inflation under particular conditions. In addition, they are not linked to a mathematically unambiguous summary measure. Test statistics based on the RMST, on the other hand, allow one to investigate the average difference between two survival curves up to a pre‐specified time point —a mathematically unambiguous summary measure. However, by emphasizing differences prior to , such test statistics may not fully capture the benefit of a new treatment in terms of long‐term survival. In this article, we introduce a graphical approach for direct comparison of weighted log‐rank tests and tests based on the RMST. This new perspective allows a more informed choice of the analysis method, going beyond power and type I error comparison.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Visualizing hypothesis tests in survival analysis under anticipated delayed effects
- Date Crossref
- 06/05/2024
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Novartis (Switzerland) pays non établi dans la noticeEntreprise
-
Janssen (United Kingdom) pays non établi dans la noticeEntreprise
-
Novartis Pharma A.G. Basel Switzerland pays non établi dans la noticeInstitution
-
Janssen Research & pays non établi dans la noticeInstitution
Novartis (Switzerland), Janssen (United Kingdom) et Novartis Pharma A.G. Basel Switzerland, avec 1 autre affiliation.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.